If you are worried that a biopsy needle could disturb cancer cells and cause them to spread, you are not alone. Needle-tract seeding has been reported in prostate cancer, but the available medical evidence suggests that this is an exceptionally rare complication rather than something you should normally expect after a biopsy.
If you need a tissue diagnosis, your prostate biopsy remains an important test for confirming whether you have cancer and determining its grade. If your MRI shows a suspicious area, your specialist can use the MRI findings to guide the biopsy and target the area that needs to be assessed.
What Does “Spreading Cancer” Mean?
If you have prostate cancer, “spreading” means that cancer cells have moved beyond where the cancer first developed. Prostate cancer can grow into nearby tissues or travel through your lymphatic system or bloodstream to other parts of your body.
This natural spread is different from needle-tract seeding. Needle-tract seeding refers to the rare possibility that cancer cells could be deposited along the path taken by a biopsy needle.
What Is Needle-Tract Seeding?
If you are having a prostate biopsy, you may come across the term “needle-tract seeding”. It refers to the rare possibility that tumour cells could become established in the tissue along the route taken by the biopsy needle.
Needle-tract seeding has been reported after prostate biopsy, but you should know that medical literature describes it as an exceptionally rare event. It is not something you should expect to happen as a normal consequence of having a biopsy.
Has It Actually Happened After Prostate Biopsy?
Yes, there have been individual reports of cancer cells being implanted along the biopsy needle path after a prostate biopsy. Cases of tumour implantation in the perineum have been reported over several decades, although they remain extremely uncommon.
If you are considering a prostate biopsy, it is important to understand that these case reports show the risk is not absolutely zero. However, they do not mean that you should expect your biopsy to cause cancer to spread.
How Rare Is Tumour Seeding?
Available evidence suggests that tumour seeding after prostate biopsy is very rare. A published review of needle-tract seeding after prostate biopsy described it as an uncommon complication and noted that its true incidence is difficult to measure.
In the historical series included in the review, the reported incidence appeared to be below 1%. However, the authors emphasised that the actual incidence could not be reliably quantified. This historical figure should therefore not be interpreted as the expected risk from a contemporary prostate biopsy.
Evidence Note
Most evidence about prostate-biopsy needle-tract seeding comes from individual case reports and historical case series rather than modern prospective studies. Rare complications may also be under-reported, while older reports often involved biopsy equipment and techniques that differ from those used today. This means researchers cannot give you a precise modern percentage risk, although the available literature consistently describes clinically recognised needle-tract seeding as rare.
Why Are There So Few Reported Cases?
Despite the large number of prostate biopsies performed, confirmed reports of needle-tract seeding remain extremely uncommon. However, the small number of published cases cannot be used to calculate a precise modern incidence because case reports and historical series may not capture every event.
A 2015 review also found that although more prostate biopsies and biopsy samples were being performed over time, there was no corresponding increase in reported cases of tumour seeding. This provides further reassurance, but it does not allow researchers to calculate a precise modern incidence.
Does a Biopsy Make Prostate Cancer Metastasise?
Current evidence does not support routine prostate biopsy as a common cause of distant metastatic spread. The rare complication described in the medical literature is local needle-tract seeding, in which tumour cells become established along the path of the biopsy needle. This is different from metastatic prostate cancer, which spreads through biological processes involving nearby tissues, the lymphatic system or bloodstream.
Needle-Tract Seeding vs Metastatic Prostate Cancer
| Feature | Needle-Tract Seeding | Metastatic Prostate Cancer |
| What it means | Cancer cells become established along the route taken by a biopsy needle | Cancer spreads naturally from the prostate to other parts of the body |
| How it occurs | Rarely, tumour cells may be displaced along the needle path | Cancer cells spread through biological processes involving nearby tissues, lymphatic vessels or the bloodstream |
| Where it occurs | Usually along or close to the biopsy needle tract | May involve lymph nodes, bones or other organs |
| Relationship to prostate biopsy | An exceptionally rare reported complication of biopsy | Not considered a routine consequence of biopsy; metastasis reflects the biological behaviour of the cancer |
| Evidence | Mainly based on isolated case reports and historical case series | Well-recognised part of the natural progression of some prostate cancers |
| Should it normally prevent biopsy? | No. The reported risk is extremely small when biopsy is clinically indicated | The purpose of biopsy is to help diagnose and assess cancer so appropriate treatment can be planned |
Can Cancer Cells Be Dislodged by a Needle?
One proposed explanation for needle-tract seeding is that tumour cells may occasionally be carried or displaced along the path of the biopsy needle. This may help explain the extremely rare cases of needle-tract seeding reported after prostate biopsy.
However, dislodged cells do not automatically survive, grow or form a new tumour. The important clinical point is that reported needle-tract seeding after prostate biopsy remains exceptionally uncommon.
Were Older Biopsy Techniques Different?
Yes. If you are reading older reports about tumour seeding after prostate biopsy, it is important to remember that some cases involved techniques and equipment that differ from those commonly used today. Some historical reports described larger needles and older biopsy methods.
For example, a 1990 case report described tumour seeding after a transperineal biopsy using a Tru-Cut needle. These older reports provide useful historical information, but they may not reflect your risk with a modern prostate biopsy.
Because needle design, gauge, biopsy technique and diagnostic pathways have changed substantially, historical case reports cannot be assumed to represent the risk associated with contemporary image-guided biopsy.
Does Transperineal Biopsy Cause Seeding?
For a transperineal prostate biopsy, rare cases of tumour seeding along the needle path have been reported. This means the theoretical risk is not absolutely zero.
However, you should not expect this to happen as a routine consequence of your biopsy. Reported cases are extremely uncommon, and needle-tract seeding is not considered a usual complication of transperineal biopsy.
What About Transrectal Biopsy?
Extremely rare cases have also been reported following transrectal prostate biopsy. For example, a 2024 case report described prostate cancer recurrence in the rectal wall that was attributed to biopsy-needle seeding.
However, an individual case report shows that something is possible, not that you are likely to experience it. Overall, the evidence indicates that needle-tract seeding remains an exceptionally uncommon complication of prostate biopsy.
Is One Biopsy Route Safer for Cancer Seeding?
If you are choosing between a transperineal and transrectal prostate biopsy, there is not enough evidence to say that one route has a clinically important advantage in preventing tumour seeding. The complication is so rare that there are not enough cases to make a reliable comparison between the two techniques.
Published case numbers should not be used to conclude that one route has a higher seeding risk, because biopsy techniques, needle sizes, clinical practice and the relative use of each approach have changed substantially over time.
If your specialist recommends a transperineal biopsy, one important reason may be its favourable infection-risk profile compared with traditional transrectal biopsy pathways. It is not because needle-tract seeding is considered a common concern with either technique.
Why Is MRI Performed Before Biopsy?
If you are being investigated for suspected prostate cancer, you will usually have an MRI before your biopsy. The scan can identify suspicious areas within your prostate and help your specialist decide whether you need a biopsy and which areas should be sampled.
UK Guidance Note
NICE recommends multiparametric MRI as the first-line investigation for people with suspected clinically localised prostate cancer. MRI findings can help determine whether a biopsy is required and identify areas that should be targeted if tissue sampling is recommended.
If multiparametric MRI has a Likert score of 1 or 2, NICE recommends considering whether biopsy can be omitted, but only after discussing the potential benefits and risks, including the remaining possibility that clinically significant cancer could be missed.
Can MRI Replace the Biopsy Completely?
If you are being assessed for suspected prostate cancer, an MRI cannot replace a biopsy in every case. An MRI can show areas that look suspicious, but a biopsy provides actual prostate tissue that can be examined under a microscope.
Your pathology report can provide information about how aggressive any cancer appears, including its Gleason score and corresponding Grade Group. Your healthcare team can then combine these findings with your PSA level, clinical stage and MRI results to assess your cancer and discuss the most appropriate next steps with you.
Why Is Tissue Diagnosis Important?
If you have a prostate biopsy, the results can do more than confirm whether cancer cells are present. A pathologist can examine your tissue samples under a microscope to assess the cancer’s microscopic features and determine its grade.
Your biopsy findings are considered alongside your PSA, MRI findings, cancer stage, general health and personal preferences when treatment options are discussed. Depending on your overall risk, these options may include active surveillance, surgery, radiotherapy or other treatments.
Is Biopsy Still a Standard Diagnostic Test?
Yes. When tissue confirmation is clinically indicated, prostate biopsy remains an important diagnostic test because it allows prostate tissue to be examined under a microscope to confirm whether cancer is present and assess its features.
Modern prostate cancer pathways usually combine your PSA results, MRI findings and biopsy results rather than relying on the biopsy alone. Your specialist may use targeted, systematic or combined sampling depending on your individual circumstances.
What Risks Are More Relevant Than Cancer Seeding?
The more commonly recognised risks after a prostate biopsy include bleeding, temporary discomfort, changes in urinary flow, urinary retention and infection. The likelihood of individual complications varies according to the biopsy approach and your individual circumstances.
- Bleeding: You may notice temporary blood in your urine or semen after the biopsy.
- Discomfort: You may experience soreness or bruising around the biopsy area.
- Urinary symptoms: Your urine flow may temporarily change after the procedure.
- Urinary retention: Occasionally, swelling, bleeding or clots can make it difficult or impossible to pass urine and urgent treatment may be needed.
- Infection: Infection can occur after prostate biopsy. Modern evidence generally supports a lower infection risk with transperineal biopsy than with traditional transrectal pathways, although individual risk also depends on the biopsy technique, antibiotic strategy and other clinical factors.
Most minor effects improve with time, but your biopsy team should explain which symptoms are expected and which require medical assessment.
When Should You Seek Urgent Help After a Prostate Biopsy?
Contact your biopsy team promptly if you develop a high or unusually low temperature, chills or shivering, worsening pain, burning when passing urine or feel significantly unwell after your biopsy, as these symptoms may indicate an infection.
Seek urgent medical assessment if you cannot pass urine or develop heavy or persistent bleeding. Call 999 or go to A&E immediately if you develop possible signs of sepsis, such as confusion or slurred speech, very fast or difficult breathing, or blue, pale, grey or blotchy skin.
Should Fear of Spreading Cancer Stop You Having a Biopsy?
If you are worried that a prostate biopsy could spread your cancer, it is important to put this extremely rare possibility into context. A biopsy can provide essential information about whether you have clinically significant prostate cancer, including its grade and other features that can guide your treatment.
If your specialist recommends a biopsy after reviewing your PSA, MRI and other risk factors, avoiding the procedure solely because you are worried that the needle will spread cancer is not supported by current evidence. Your specialist can explain the benefits and risks of the biopsy so you can make an informed decision.
Can Some Men Avoid Biopsy?
If your multiparametric MRI has a Likert score of 1 or 2, it may be appropriate to consider omitting a prostate biopsy in some circumstances. NICE recommends that your healthcare team considers whether a biopsy can be omitted after discussing the benefits, disadvantages and the remaining possibility of clinically significant cancer with you.
A raised PSA does not automatically mean that you need a biopsy. Your specialist will consider your MRI findings alongside your PSA level, PSA density, examination findings, family history and other individual risk factors before discussing whether biopsy is appropriate for you.
What Should You Ask Before Your Biopsy?
Before your prostate biopsy, ask why your specialist recommends the procedure and what your MRI showed. You can also ask which biopsy approach will be used, what type of anaesthetic you will have and what the possible risks are.
If you take blood-thinning medicines, such as warfarin, apixaban, rivaroxaban, clopidogrel or aspirin, make sure your biopsy team knows before the procedure. You may need specific instructions about whether and when your medication should be changed, so do not stop or alter prescribed blood-thinning treatment without advice from the healthcare team managing your care.
It is also worth asking how your biopsy results could affect your diagnosis and treatment options. If you are considering specialist prostate biopsy services in London, you can discuss your individual diagnostic pathway and any concerns with your specialist beforehand.
Myth vs Fact
| Myth | Fact |
| A prostate biopsy normally causes cancer cells to spread around the body. | Current evidence does not support routine prostate biopsy as a common cause of distant metastatic spread. |
| If cancer cells touch the biopsy needle, they will form another tumour. | Tumour cells may occasionally be displaced along a needle tract, but displaced cells do not automatically survive, grow or establish a clinically significant tumour. |
| Needle-tract seeding has never happened after prostate biopsy. | Rare cases have been reported, so the risk cannot be described as zero. However, clinically recognised needle-tract seeding is exceptionally uncommon. |
| Transperineal biopsy completely eliminates the risk of cancer seeding. | Rare cases have been reported after both transperineal and transrectal biopsy, and there is not enough evidence to establish a meaningful difference in seeding risk between modern biopsy routes. |
| You should avoid a biopsy because it might spread cancer. | When a biopsy is clinically indicated, it provides important information about whether cancer is present and how aggressive it appears. Fear of needle-tract seeding alone is not supported by current evidence as a reason to avoid a recommended biopsy. |
Key Takeaways
- Needle-tract seeding after prostate biopsy has been reported, but published evidence suggests it is exceptionally rare.
- Needle-tract seeding is different from metastatic prostate cancer spreading naturally through the bloodstream or lymphatic system.
- There is no good clinical evidence that routine prostate biopsy commonly causes prostate cancer to spread around the body.
- MRI can help determine whether a biopsy is needed and guide sampling towards suspicious areas of the prostate.
- A biopsy remains important when tissue confirmation is clinically necessary because it can confirm cancer and provide information about its grade.
- The risks you are more likely to experience after biopsy include temporary bleeding, discomfort, urinary symptoms and, less commonly, infection or urinary retention.
Frequently Asked Questions
1. Can a prostate biopsy spread cancer?
Needle-tract seeding has been reported after prostate biopsy, but it is an exceptionally rare complication. Current evidence does not suggest that routine prostate biopsy commonly causes prostate cancer to spread around the body.
2. What is needle-tract seeding?
Needle-tract seeding occurs when cancer cells become deposited along the path taken by a biopsy needle and subsequently establish a tumour deposit. Although this has been documented after prostate biopsy, published reports describe it as rare.
3. How common is cancer seeding after a prostate biopsy?
The true incidence is difficult to determine because confirmed cases are extremely uncommon. A 2015 review suggested an incidence below 1% based on historical published series, but the authors could not reliably quantify the true risk. This figure should therefore not be interpreted as your individual risk from a modern prostate biopsy.
4. Can a biopsy make prostate cancer metastasise?
Current evidence does not support the idea that routine prostate biopsy commonly causes prostate cancer to metastasise. The rare complication described in the literature is local needle-tract implantation, which is different from the usual biological process of metastatic spread.
5. Can cancer cells be dislodged by the biopsy needle?
Yes. One proposed mechanism for needle-tract seeding is that tumour cells may occasionally be displaced along the path of the biopsy needle. However, displaced cells do not automatically survive or develop into another tumour, and clinically recognised needle-tract seeding after prostate biopsy remains exceptionally rare.
6. Can transperineal biopsy cause cancer seeding?
Rare cases of needle-tract seeding have been reported after transperineal biopsy, so the theoretical risk is not zero. However, it is sufficiently unusual that it is not considered a routine expected complication of the procedure.
7. Can transrectal biopsy cause cancer seeding?
Extremely rare cases have also been reported following transrectal biopsy. Individual case reports show that needle-tract implantation is possible, but they do not indicate that it is a common consequence of the procedure.
8. Is transperineal biopsy safer than transrectal biopsy for cancer spread?
There is not enough evidence to establish a clinically important difference in tumour-seeding risk between modern transperineal and transrectal biopsies. The transperineal approach may offer an infection-risk advantage over traditional transrectal biopsy pathways, but this is separate from the question of tumour seeding.
9. Why is a prostate biopsy still recommended if there is a risk of cancer seeding?
A biopsy provides tissue that can be examined under a microscope to confirm whether cancer is present and determine its grade. When a biopsy is clinically indicated, the benefit of obtaining an accurate diagnosis generally outweighs the exceptionally small risk of needle-tract seeding.
10. Can you avoid a prostate biopsy if you are worried about cancer spreading?
In some people, it may be appropriate to consider omitting a biopsy depending on the overall clinical risk and MRI findings. NICE recommends considering this option when multiparametric MRI has a Likert score of 1 or 2, but only after discussing the benefits, disadvantages and remaining possibility of clinically significant cancer.
Final Thoughts: Can a Prostate Biopsy Spread Cancer?
Although needle-tract seeding after a prostate biopsy has been reported, it is an exceptionally rare complication and should not be confused with the usual spread of prostate cancer. When tissue confirmation is clinically indicated, the benefits of accurately diagnosing and grading prostate cancer generally outweigh the very small potential risk of needle-tract seeding.
If you’re considering a prostate biopsy in London and would like to talk through why it has been recommended, our team at Prostate Clinic London would be happy to discuss your PSA or MRI findings, biopsy options and any concerns you may have. If it feels helpful, we can also arrange a consultation.
References:
- National Institute for Health and Care Excellence (2019) Prostate cancer: diagnosis and management. NICE guideline NG131. Last reviewed 13 August 2025. Available at: https://www.nice.org.uk/guidance/ng131
- British Association of Urological Surgeons (2024) Transperineal ultrasound-guided biopsies of the prostate gland. Leaflet No. O24/107. Available at: https://www.baus.org.uk/_userfiles/pages/files/patients/leaflets/Transperineal%20biopsies.pdf
- Volanis, D., Neal, D.E., Warren, A.Y. and Gnanapragasam, V.J. (2015) ‘Incidence of needle-tract seeding following prostate biopsy for suspected cancer: a review of the literature’, BJU International, 115(5), pp. 698–704. Available at: https://pubmed.ncbi.nlm.nih.gov/24958224/
- Ryan, P.G. and Peeling, W.B. (1990) ‘Perineal prostatic tumour seedling after “Tru-Cut” needle biopsy: case report and review of the literature’, European Urology, 17(2), pp. 189–192. Available at: https://pubmed.ncbi.nlm.nih.gov/2178943/
- Hakariya, T. et al. (2024) ‘Recurrence of mucinous prostate cancer in rectal wall due to needle-track seeding from previous transrectal prostate biopsy’, IJU Case Reports, 7(6), pp. 499–502. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC11531872/
- Spicchiale, C.F. et al. (2024) ‘A challenging diagnosis of prostate cancer seeding in the perineal needle-tract after transperineal biopsy: is PET-CT the imaging of choice?’, Urology Case Reports, 57, 102852. Available at: https://pubmed.ncbi.nlm.nih.gov/39398264/
- Hu, J.C. et al. (2024) ‘Transperineal versus transrectal magnetic resonance imaging-targeted and systematic prostate biopsy to prevent infectious complications: the PREVENT randomized trial’, European Urology, 86(1), pp. 61–68. Available at: https://pubmed.ncbi.nlm.nih.gov/38212178/
- NHS (2026) Sepsis. Last reviewed 14 May 2026. Available at: https://www.nhs.uk/conditions/sepsis/